Download Presentazione di PowerPoint

Pisa 4-5 Dicembre2014
XXIV MITO MEETING:
CONSIGLIO DIRETTIVO
Centri e soci
 153 centri MITO (Ginecologie ed Oncologie, 2 nuovi)
 10 centri MITO (gruppo traslazionale)
 461 soci (7 nuovi)
Nuovi soci MITO-group
• Romualdo Nieddu - Ginecologia Ospedale Oncologico Regionale “A. Businco”- Cagliari
• Gloria Mittica - Oncologia Medica IRCC Università degli Studi di Torino – Candiolo (To)
• Celeste Cagnazzo - Oncologia Medica IRCC Università degli Studi di Torino - Candiolo (To)
• Antonio Perrone – Ginecologia Ospedale “Vito Fazzi” – Lecce
• Piera Gargiulo - Oncologia Medica Università Federico II- Napoli
• Giuseppe Tonini- Oncologia Medica Campus Biomedico - Roma
• Chiara Della Pepa - Oncologia Medica Campus Biomedico - Roma
MITO Pub
 Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent
ovarian cancer: Analysis of the CALYPSO trial.
Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I,
Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M. Gynecol Oncol. 2014 Oct 2. pii: S00908258(14)01344-4.
 Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza
MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C,
Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica
I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. J Clin Oncol. 2014 Oct 20;32(30):3374-82.
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma.
Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata
S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101.
 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade
Serous Carcinomas.
Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E,
Glasspool RM, Ray-Coquard I, Gershenson D. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-S13. J Clin Oncol. 2014
Oct 20;32(30):3374-82.
MITO Pub
 Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian
trials in ovarian cancer (MITO-9).
Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari
V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata
S. Oncology. 2014;86(5-6):351-8.
 Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer
(MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici
PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C,
Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F;
Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers
Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological
Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Lancet Oncol. 2014
Apr;15(4):396-405.
 Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for
ovarian cancer).
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U,
Pignata S; OCTAVIA Investigators. Eur J Cancer. 2014 Mar;50(4):862-3.
MITO Pub
Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International
Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of
Trophoblastic Disease, and the Gynecologic Cancer InterGroup.
Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A,
Kim JW, Xiang Y, Berkowtiz R, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16.
 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus
and Cervix.
Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso
D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24.
Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors.
Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney
ME, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54.
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary.
Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D,
Mirza MR, Ray-Coquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41.
MITO Pub
 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary.
Glasspool RM, Martín AG, Millan D, Lorusso D, Avall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J,
Ledermann JA. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9.
 Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of
the Uterus.
Pautier P, Ji Nam E, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, RayCoquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7.
 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma.
Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J,
Oza A, Brown J. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9.
 Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International
Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of
Trophoblastic Disease, and the Gynecologic Cancer InterGroup.
Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda
A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16.
MITO Pub
 Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults.
Mangili G, Sigismondi C, Lorusso D, Pignata S. Clin Oncol. 2014 Sep 1;32(25):2814-5.
Progression-Free Survival by Local Investigator Versus Independent Central Review: Comparative Analysis
of the AGO-OVAR16 Trial.
Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, Del Campo JM,
Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Gynecol Oncol. 2014 Nov 27.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA
open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira
D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. J Clin Oncol. 2014 May 1;32(13):1302-8.
18……
Studi in corso
e in via di attivazione…
ONGOING
•MITO 8 ENGOT OV1 (INT Napoli)
•TUMORI RARI MITO 9 (Bari, ISR Milano)
•MITO 14-borderline (FBF Roma)
•MITO 15 YONDELIS (Gemelli-Roma)
•MITO 16a- MANGO OV 2 (INT Napoli)
•MITO 16b- MANGO OV 2 INT Napoli)
•MITO 17(INT Napoli)
•MITO 18 Horse (Roma Gemelli)
•MITO 19- Meta encefaliche (Sapienza-Roma)
•MITO 20 Piccole cellule (Gemelli-Roma)
•MITO 21 - BRCA 1 and BRCA 2 mutation carriers (Mirano)
•MITO 22 –Sierosi di basso grado (Napoli)
•MITO Cerv 2 (Napoli)
•TOTEM-Endometrio (Mango)
•MITO BEVAEND 2- Bevacizumab endometrio (Roma)
•EXPRESSION OVAR 4 (INT Milano)
PROFIT /ENGOT
• SOLO2(Napoli)
• MILO(Napoli)
•NOVA(Milano)
•TRINOVA 2 (Roma)
•TRINOVA 3 (Roma)
GCIG
•DESKTOP III (Napoli)
•ANZGOG Sintomi (Napoli)
Relazioni Internazionali
GCIG
• Bryce, Pignata, Lorusso, Mezzanzanica, Bellati
Savarese
• Cervix Brainstorming (Scambia, Greggi, Fagotti)
• Japan OCC 2015 Scambia Lorusso
ENGOT
• Pignata, Bryce
• Fasi 1 Daniele
• Traslazionale Mezzanzanica
GCA
• Marchetti, Salutari
MITO ma quanto ci costi?
SEDE
ANNO
PERNOTTAMENTO
PARTECIPANTI
COSTO
ROMA
2009
77
55.000
CATANIA
2010
72
44.000
PISA
2011
54
42000
NAPOLI
2011
88
64000
VERONA
2012
80
58000
MILANO
2012
89
72500
BARI
2013
61
55000
ROMA
2013
85
73000
SIRACUSA
2014
60
53000
PISA
2014
78
51000+11500
TOTALE
RIUN D.M. + RIUN
TRASL
RIUN D.M. + RIUN
TRASL
RIUN D.M. + RIUN
TRASL
RIUN D.M. + RIUN
62 500 TRASL
Programma 2013-2015
•
Revisione statuto per votazioni
•
Implementare il gruppo
(Scibilia-Losito promotori)
degli
anatomo-patologi
•
Continuare attività del gruppo qualità
•
Elaborazione di protocolli che possano coinvolgere i
radioterapisti (Savarese-Lorusso)
•
Streaming e nuova struttura riunione MITO
•
Programmi specifici dei vari gruppi